CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 31 enrolled
Drug / intervention
OPTRELL Mapping Catheterdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04983797
NCT04983797N/ACompleted
CompareCT.gov

Clinical Evaluation of Arrhythmia Mapping With the Multi-Electrode OPTRELL™ Mapping Catheter

Biosense Webster, Inc.·interventional·Posted Jul 30, 2021·Updated Jul 3, 2023

In Brief

A clinical study evaluating OPTRELL Mapping Catheter for Scar-related Atrial Tachycardia and 4 related conditions. Completed, enrolled 31 participants across 3 sites in 2 countries.

Detailed Summary

The purpose of this study is to assess the performance and safety for the use of the OPTRELL Catheter for intracardiac mapping in the atria and ventricles.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsScar-related Atrial Tachycardia, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Tachycardia, Ventricular, Ventricular Premature Complexes
CountriesBelgium, Lithuania
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedJul 30, 2021
Enrollment StartAug 25, 2021
Primary CompletionNov 4, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.9 years ago

Interventions

OPTRELL Mapping Catheterdevice

Participants scheduled to have a clinically-indicated catheter mapping and ablation using OPTRELL mapping catheter for the management of Atrial procedure (Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation) and Ventricular procedures (Ventricular Tachycardia, Premature Ventricular Complex).